Endocrine Abstracts

TSH secreting pituitary adenomas are rare tumours for which the treatment of choice is neurosurgery but in some cases medical treatment with somatostatin analogs (SSA) can lead to a good control of symptoms and shrinkage of the tumour.The objective of this study was to review 30 patients diagnosed with TSH-omas between October 1981–July 2014, followed-up for a median of 43.93 months (1.12–192.11) in our University Hospital from Lyon, France.</p...

Introduction: 15% of pituitary tumors are considered as aggressive based on resistance to conventional treatment. Less than 40% of these cases respond to temozolomide treatment underlining the need for new therapeutic options. The PI3K/Akt/mTOR pathway, upregulated in different pituitary tumors subtypes, can be targeted by different drugs in particular BKM 120, a pure PI3K inhibitor, and BEZ235, a dual PI3K/mTOR inhibitor.Objective: To study the anti-tum...

The thyrotroph tumors or pituitary neuroendocrine tumors (PitNET) classify as tumors of Pit-1 family. These tumors are rare and may be monohormonal, secreting only TSH, or plurihormonal, secreting TSH-GH±PRL, with or without acromegaly. The objectives of this retrospective study were to confirm the frequency of the plurihormonal subtype and to compare the clinical, biological and pathological characteristics of these two pathological subtypes. We retrospectively studied t...

Context: Somatostatin receptor type 5 (SST5) is inconsistently expressed by corticotroph tumors, with higher expression found in corticotropinomas having ubiquitin-specific protease 8 (USP8) mutations.Aims: To study the correlation between characteristics of corticotropinomasand SST5 expression/USP8 mutation status; to describe the response to pasireotide in 5 patients.Design: Retrospective cohort study.Metho...